Focus on Levels of Awareness and Perceptions Regarding hsCRP in Identifying Systemic Inflammation in ASCVD, CKD and Heart Failure Management

NCT07160829 | Completed

• 2 other identifiers: DAS-8416U1111-1315-0755
• Study Type: observational
• Target: 608
• Locations: 4 countries
• Sites: 4

Brief Summary

This is a survey-based study conducted among cardiologists and nephrologists treating people with Atherosclerotic Cardiovascular Disease (ASCVD), Heart Failure (HF) and Chronic Kidney Disease (CKD). Study participants will be recruited to complete self-administered online survey. The purpose of this research is to gather real-world evidence related to attitudes around systemic inflammation and specifically the awareness, perception, drivers and barriers, and use of hsCRP in clinical practice to identify systemic inflammation in people with ASCVD+CKD and HF.

Conditions

Chronic Kidney Disease; Atherosclerotic Cardiovascular Disease; Heart Failure

Outcome Measures

Primary Outcomes (1)

• Perceptions towards role of systemic inflammation in identification, treatment, management of ASCVD+CKD and HF

  Multi-select from a defined list; 7-point Likert scale where 1=Not at all Important and Single-select from a defined list; Numerical; 7=Extremely Important; 7-point Likert scale where 1=Strongly Disagree and 7=Strongly Agree. Cardiologists and nephrologists' perceptions towards the role of systemic inflammation in the identification, treatment and management of people with Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease (ASCVD+CKD) and Heart Failure (HF)

  At the time of survey response (Day 1)

Study Arms (2)

Nephrologist Group

This group includes nephrologists treating people with ASCVD and CKD.

Other: No treatment given

Cardiologist Group

This group includes cardiologist treating people with ASCVD and CKD.

Other: No treatment given

Interventions

No treatment given OTHER

No treatment given

Cardiologist Group; Nephrologist Group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population includes cardiologists and nephrologists treating people with Atherosclerotic Cardiovascular Disease (ASCVD), Heart Failure (HF) and Chronic Kidney Disease (CKD)

You may qualify if:

• Informed consent obtained before any study related activities (study-related activities are any procedure related to recording of data according to the protocol).
• Male or female, age above 18 years at the time of signing informed consent.
• Is a nephrologist or cardiologist. Cardiologists may be a mix of Interventional Cardiology, Heart Failure (HF) Specialist, General Cardiology, Preventative Cardiology, Cardiac Electrophysiology, Cardio-Oncology or Echocardiography (India only).
• Has been in specialty practice greater than or equal to 3 years.
• If cardiologist, sees at least 15 people with Atherosclerotic Cardiovascular Disease (ASCVD) with or without Chronic Kidney Disease (CKD) per month.
• If nephrologist, sees at least 20 people with ASCVD and CKD per month.

You may not qualify if:

• Previous participation in this study. Participation is defined as having given informed consent in this study.
• Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
• If nephrologist, is only using dialysis to treat people with ASCVD and CKD.

Sponsors & Collaborators

• Novo Nordisk A/S: lead

Study Sites (4)

Novo Nordisk Investigational Site

Sydney, 2060, Australia

Location

Novo Nordisk Investigational Site

Bangalore, Karnataka, India

Location

Novo Nordisk Investigational Site

Seoul, South Korea

Location

Novo Nordisk Investigational Site

Bangkok, Thailand

Location

MeSH Terms

Conditions

Atherosclerosis; Heart Failure; Renal Insufficiency, Chronic

Condition Hierarchy (Ancestors)

Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases; Cardiovascular Diseases; Heart Diseases; Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Clinical Transparency dept. 2834

  Novo Nordisk A/S

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 29, 2025
• First Posted: September 8, 2025
• Study Start: September 18, 2025
• Primary Completion: October 30, 2025
• Study Completion: October 30, 2025
• Last Updated: February 11, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will share

Locations

AU (1); KR (1); IN (1); TH (1)